Peptides for Muscle Growth: Evidence and Limits

Peptides for muscle growth are not a shortcut to larger or stronger muscles. The prescription compounds most often discussed are GH-axis secretagogues: sermorelin, CJC-1295 with ipamorelin, and tesamorelin. They signal the pituitary to increase growth hormone, which can raise IGF-1. Human evidence concerns hormone levels and body composition in older adults, people with low GH, or people with HIV-associated changes in fat distribution—not hypertrophy in healthy trained adults. That distinction is the honest starting point.

What peptides for muscle growth actually do

These compounds act upstream of growth hormone rather than supplying testosterone or an anabolic steroid. They are not interchangeable:

• Sermorelin is an analogue of growth hormone-releasing hormone (GHRH). It prompts the pituitary to release GH, provided the pituitary can respond. The broader clinical context is covered in sermorelin benefits.
• CJC-1295 is also a GHRH analogue. Ipamorelin acts at the ghrelin receptor. The combination targets two signals that converge on GH release; CJC-1295 and ipamorelin explains that pairing in detail.
• Tesamorelin is a GHRH analogue with the strongest drug-specific body-composition evidence of the three, but that evidence comes from adults with HIV-associated lipodystrophy and addresses abdominal fat—not bodybuilding.

Raising GH or IGF-1 establishes that a pathway was engaged. It does not establish that new contractile muscle was built or that performance improved.

The clinical use case is not the same as a gym goal. Diagnosed adult GH deficiency is an endocrine disorder; an age-related decline in GH or an interest in recovery is not that diagnosis. Before attributing low muscle mass to the GH axis, a clinician considers training exposure, energy and protein intake, sleep, thyroid function, sex-hormone status, medication effects, and illness. A normal hormone response after an injection would only show that the signaling system reacted. It would not show that GH was the factor limiting hypertrophy. This is why mechanism alone cannot identify a “best” compound: the population, comparison group, and outcome determine whether evidence applies. A laboratory result must also be interpreted against age and clinical context.

What the human studies found

The evidence is useful when its population and endpoint stay attached to the number. Four studies show why a hormone response, lean mass, hypertrophy, and strength cannot be treated as synonyms.

In the 2008 Annals of Internal Medicine MK-677 trial, the same group that gained fat-free mass also gained more body weight, had a 5 mg/dL average rise in fasting glucose, and showed lower insulin sensitivity (Nass et al., 2008). MK-677 is not a Promise product; it is relevant because it tests the same broad strategy of stimulating the GH axis.

The CJC-1295 trial confirmed sustained GH and IGF-1 changes but was short and did not measure muscle growth (Teichman et al., JCEM 2006). It tested long-acting CJC-1295 with DAC, not the short-acting form in the Promise combination, so its schedule and hormone changes do not validate the blend. The ipamorelin study likewise measured pharmacokinetics and GH release, not training outcomes (Gobburu et al., Pharmaceutical Research 1999). The tesamorelin lean-mass result came from a specific clinical population in a trial whose primary purpose was reducing visceral fat (Falutz et al., NEJM 2007). None of those results supplies an effect size for a healthy athlete.

Lean mass is not the same as muscle hypertrophy

Lean mass is everything that is not fat: muscle, water, organs, bone, and other tissue. DXA can detect a lean-mass change without proving that muscle fibers grew. GH-axis drugs can also cause fluid retention, so a scale or scan can move without a proportional change in contractile tissue. Strength and physical function are harder endpoints to dismiss.

A 2008 Annals of Internal Medicine systematic review of GH in healthy people found a 2.1 kg average increase in lean body mass, yet strength and exercise capacity did not appear to improve (Liu et al., 2008). That review studied growth hormone itself rather than these secretagogues, so it cannot define their exact effects. It does show why more lean mass is not automatically more useful muscle.

Prescription care versus a grey-market vial

A product page that calls something a muscle growth peptide may collapse mechanism, animal work, hormone measurements, and human outcomes into one claim. A prescription route keeps those questions separate. It connects a named patient, a licensed provider, a pharmacy label, and follow-up to the medication. A vial sold without a prescription skips that clinical chain and leaves no prescriber accountable for whether the compound fits the patient's history.

At Promise, these products are dispensed as compounded medications, which are different from FDA-approved products: compounded sermorelin is not FDA-approved, compounded CJC-1295/ipamorelin is not FDA-approved, and compounded tesamorelin is not FDA-approved. FDA explains that compounded drugs do not undergo its premarket review for safety, effectiveness, or quality (FDA, Human Drug Compounding Laws).

Tesamorelin also exists as branded Egrifta WR. Its U.S. label covers reduction of excess abdominal fat in adults with HIV and lipodystrophy and expressly says it is not indicated for weight-loss management (Egrifta WR prescribing information, March 2025). That indication does not transfer to compounded tesamorelin or to muscle building. A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision belongs to the patient and prescriber.

What a prescriber considers

A clinician starts with the reason for the request, not a peptide ranking. Baseline IGF-1, glucose control, pituitary function, medication history, pregnancy status, prior or active malignancy, edema, and carpal-tunnel symptoms can all change the risk assessment. Sleep, calorie intake, protein intake, training history, thyroid disease, and other causes of low muscle mass also matter.

The prescriber sets the dose and follow-up plan. Useful follow-up separates hormone response from the outcome the patient actually wants: IGF-1 and glucose are laboratory measures; waist or DXA data describe body composition; a training log or strength test describes performance. A licensed provider reviews every request at Promise, and not everyone qualifies.

The actual levers for building muscle

Progressive resistance training and adequate dietary protein remain the evidence-based levers for hypertrophy. In a meta-analysis of 49 resistance-training trials with 1,863 participants, protein supplementation added an average 0.30 kg of fat-free mass and 2.49 kg to one-repetition-maximum strength compared with training alone; gains in fat-free mass did not increase further above about 1.62 g/kg/day of total protein (Morton et al., British Journal of Sports Medicine 2018). That population result is context, not an individual nutrition prescription.

For tested athletes, there is another firm boundary: the 2026 World Anti-Doping Agency list prohibits CJC-1295, sermorelin, tesamorelin, and ipamorelin at all times, in and out of competition. A prescription does not erase anti-doping rules.

The defensible role of a GH-axis peptide is therefore narrow: a clinician may consider it for an appropriate patient after screening and with measurable follow-up. It is not a substitute for training, food, recovery, or evidence of actual hypertrophy. For a side-by-side view of this category, see the best-studied HGH peptides.